| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | -0.24 | 0.001 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.15 | 0.001 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.16 | 0.001 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.002 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |